Posted: Monday, May 8, 2023
Paul Sieber, MD, of Keystone Urology, Lancaster, Pennsylvania, and colleagues evaluated whether hypertension, hyperlipidemia, diabetes, or their co-occurrence could predict cardiovascular events in patients with prostate cancer who initiated androgen-deprivation therapy. The results of this study, presented during the American Urological Association (AUA) Annual Meeting 2023 (Abstract MP06-07) and published in The Journal of Urology, provided insight to the optimal evaluation and management of cardiovascular risk in this patient population.
“[The] presence of comorbidities in men with prostate cancer starting [androgen-deprivation therapy] treatment, compared to men with none of these, was associated with greater risk for a cardiovascular event,” the investigators concluded. “Evaluating the presence of these frequent comorbidities could provide a simple, readily available framework for health-care providers to identify patients with prostate cancer at greatest risk for cardiovascular events.”
The study authors queried the U.S. Claims Database for men diagnosed with prostate cancer who received androgen-deprivation therapy from 2010 to 2019 (n = 10,530). Using these data, they evaluated whether the presence of one, two, or three of these comorbidities, or as mutually exclusive groups, correlated with a higher risk of cardiovascular event up to 3 years after androgen-deprivation therapy.
A total of 934 men experienced a cardiovascular event postindex. Compared with patients who did not have comorbidities, those with all three comorbidities had a significantly higher risk of cardiovascular events as identified by Cox regression model (P < .0010). Furthermore, the presence of two comorbidities indicated a significantly increased risk of cardiovascular events (P < .001). Of note, there was no increased risk of cardiovascular events among patients with one comorbidity.
Disclosure: No disclosure information was provided.